Revolution Medicines (RVMD) surges 37% on Phase 3 breakthrough: daraxonrasib nearly doubles median survival to 13.2 months vs. 6.7 months on chemo — hazard ratio 0.40, risk of death cut by 60%
Revolution Medicines (NASDAQ: RVMD) surged approximately 37% in premarket...
